An audit of high dose-rate prostate brachytherapy treatment planning at six Swedish clinics.

Frida Dohlmar, Sakarias Johansson, Torbjörn Larsson, Michael Sandborg, Åsa Carlsson Tedgren
Author Information
  1. Frida Dohlmar: Medical Radiation Physics, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
  2. Sakarias Johansson: Department of Oncology, Karolinska University Hospital, Stockholm, Sweden.
  3. Torbjörn Larsson: Department of Mathematics, Linköping University, Linköping, Sweden.
  4. Michael Sandborg: Medical Radiation Physics, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
  5. Åsa Carlsson Tedgren: Medical Radiation Physics, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.

Abstract

PURPOSE: High dose-rate prostate brachytherapy has been implemented in Sweden in the late 1980s and early 1990s in six clinics using the same schedule: 20 Gy in two fractions combined with 50 Gy in 25 fractions with external beam radiation therapy. Thirty years have passed and during these years, various aspects of the treatment process have developed, such as ultrasound-guided imaging and treatment planning system. An audit was conducted, including a questionnaire and treatment planning, which aimed to gather knowledge about treatment planning methods in Swedish clinics.
MATERIAL AND METHODS: A questionnaire and a treatment planning case (non-anatomical images) were sent to six Swedish clinics, in which high-dose-rate prostate brachytherapy is performed. Treatment plans were compared using dosimetric indices and equivalent 2 Gy doses (EQD). Treatment planning system report was used to compare dwell positions and dwell times.
RESULTS: For all the clinics, the planning aim for the target was 10.0 Gy, but the volume to receive the dose differed from 95% to 100%. Dose constraints for organs at risk varied with up to 2 Gy. The dose to 90% of target volume ranged from 10.0 Gy to 11.1 Gy, equivalent to 26.0 Gy EQD and 31.3 Gy EQD, respectively. Dose non-homogeneity ratio differed from 0.18 to 0.32 for clinical target volume (CTV) in treatment plans and conformity index ranged from 0.52 to 0.59 for CTV.
CONCLUSIONS: Dose constraints for the organs at risk are showing a larger variation than that reflected in compared treatments plans. In all treatment plans in our audit, at least 10 Gy was administered giving a total treatment of 102 Gy EQD, which is in the upper part of the prescription doses published in the GEC/ESTRO recommendations.

Keywords

References

  1. Radiother Oncol. 1997 Sep;44(3):237-44 [PMID: 9380822]
  2. Med Phys. 2011 Feb;38(2):782-801 [PMID: 21452716]
  3. Phys Imaging Radiat Oncol. 2018 Mar 21;5:85-87 [PMID: 33458374]
  4. Phys Med Biol. 2016 Feb 7;61(3):1155-70 [PMID: 26760757]
  5. Med Phys. 2013 Nov;40(11):111724 [PMID: 24320432]
  6. Radiother Oncol. 1997 Sep;44(3):245-50 [PMID: 9380823]
  7. J Contemp Brachytherapy. 2016 Jun;8(3):201-7 [PMID: 27504129]
  8. J Contemp Brachytherapy. 2012 Jun;4(2):81-91 [PMID: 23349649]
  9. Brachytherapy. 2016 Jan-Feb;15(1):102-11 [PMID: 26561276]
  10. Radiother Oncol. 2018 Apr;127(1):81-87 [PMID: 29496280]
  11. J Appl Clin Med Phys. 2014 Nov 08;15(6):5055 [PMID: 25493531]
  12. Phys Med Biol. 2001 Feb;46(2):323-31 [PMID: 11229717]
  13. Radiother Oncol. 2005 Feb;74(2):157-61 [PMID: 15734203]
  14. Australas Phys Eng Sci Med. 2015 Mar;38(1):55-61 [PMID: 25481387]
  15. J Appl Clin Med Phys. 2019 Apr;20(4):66-74 [PMID: 30882986]
  16. Radiother Oncol. 2013 Jun;107(3):325-32 [PMID: 23773409]
  17. Int J Radiat Oncol Biol Phys. 1991 Jan;20(1):135-9 [PMID: 1993622]
  18. Brachytherapy. 2015 Mar-Apr;14(2):279-88 [PMID: 25447341]
  19. J Urol. 2005 Sep;174(3):882-7 [PMID: 16093980]
  20. Radiother Oncol. 2014 Jan;110(1):199-212 [PMID: 24299968]
  21. Acta Oncol. 2007;46(7):909-17 [PMID: 17917823]
  22. J Med Phys. 2006 Apr;31(2):89-94 [PMID: 21206671]
  23. J Contemp Brachytherapy. 2010 Sep;2(3):117-128 [PMID: 27853473]
  24. Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):586-91 [PMID: 12738336]
  25. Radiother Oncol. 2004 Oct;73(1):73-7 [PMID: 15465149]
  26. Brachytherapy. 2012 Jan-Feb;11(1):20-32 [PMID: 22265435]
  27. Radiother Oncol. 2005 Jun;75(3):311-7 [PMID: 15890425]
  28. Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):515-24 [PMID: 9457842]
  29. Brachytherapy. 2008 Jan-Mar;7(1):12-6 [PMID: 18037356]
  30. Acta Oncol. 2015 Jun;54(6):875-81 [PMID: 25362844]

Word Cloud

Created with Highcharts 10.0.0Gytreatmentplanning0clinicsbrachytherapyauditplansEQDprostatesixSwedishtarget10volumeDosedose-rateusingfractionsyearssystemquestionnaireTreatmentcompareddosimetricindicesequivalent2dosesdwelldosedifferedconstraintsorgansriskrangedCTVPURPOSE:HighimplementedSwedenlate1980searly1990sschedule:20twocombined5025externalbeamradiationtherapyThirtypassedvariousaspectsprocessdevelopedultrasound-guidedimagingconductedincludingaimedgatherknowledgemethodsMATERIALANDMETHODS:casenon-anatomicalimagessenthigh-dose-rateperformedreportusedcomparepositionstimesRESULTS:aimreceive95%100%varied90%11126313respectivelynon-homogeneityratio1832clinicalconformityindex5259CONCLUSIONS:showinglargervariationreflectedtreatmentsleastadministeredgivingtotal102upperpartprescriptionpublishedGEC/ESTROrecommendationshigh

Similar Articles

Cited By

No available data.